Elicio Therapeutics Inc
Research Elicio Therapeutics Inc (ELTX) on Bullrun: market cap USD 41.39M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerELTX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 41.39M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 8.22M
- Free cash flow-USD 8.17M
Valuation Snapshot
latest market cap is USD 41.39M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 39.57M | -USD 36.97M | n/a | -2.58 | USD 18.56M | USD 9.41M | USD 1.64M |
| FY2024 | USD 0 | -USD 51.90M | -USD 37.16M | n/a | -4.25 | USD 17.62M | USD 20.03M | -USD 11.31M |
| FY2023 | USD 0 | -USD 35.20M | -USD 32.76M | n/a | -6.96 | USD 12.89M | USD 6.92M | USD 11.37M |
| FY2022 | USD 2.30M | -USD 28.21M | -USD 22.83M | 100.0% | -89.27 | USD 6.16M | USD 7.48M | -USD 102.15M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 41.39M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 141.69M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 56.25M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 80.11M | n/a | n/a | n/a |
About Elicio Therapeutics Inc
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Elicio Therapeutics Inc's market cap?
Elicio Therapeutics Inc's market capitalization is USD 41.39M.
What does Elicio Therapeutics Inc do?
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations.